S&P 500   2,967.42 (-0.10%)
DOW   26,828.08 (+0.04%)
QQQ   191.15 (+0.02%)
AAPL   236.65 (+0.19%)
FB   183.49 (-0.38%)
MSFT   139.68 (+0.00%)
GOOGL   1,219.93 (+0.35%)
AMZN   1,727.14 (-0.28%)
CGC   18.65 (-4.01%)
MU   44.95 (-0.35%)
BABA   171.51 (-0.83%)
GE   8.78 (-0.23%)
AMD   30.14 (+1.31%)
T   37.33 (-0.67%)
F   8.81 (+0.34%)
ACB   3.45 (-6.25%)
PRI   121.46 (-0.19%)
NFLX   284.59 (+0.59%)
BAC   29.10 (+0.66%)
GILD   64.92 (+1.45%)
DIS   129.65 (-0.28%)
S&P 500   2,967.42 (-0.10%)
DOW   26,828.08 (+0.04%)
QQQ   191.15 (+0.02%)
AAPL   236.65 (+0.19%)
FB   183.49 (-0.38%)
MSFT   139.68 (+0.00%)
GOOGL   1,219.93 (+0.35%)
AMZN   1,727.14 (-0.28%)
CGC   18.65 (-4.01%)
MU   44.95 (-0.35%)
BABA   171.51 (-0.83%)
GE   8.78 (-0.23%)
AMD   30.14 (+1.31%)
T   37.33 (-0.67%)
F   8.81 (+0.34%)
ACB   3.45 (-6.25%)
PRI   121.46 (-0.19%)
NFLX   284.59 (+0.59%)
BAC   29.10 (+0.66%)
GILD   64.92 (+1.45%)
DIS   129.65 (-0.28%)
Log in

G1 Therapeutics Stock Price, News & Analysis (NASDAQ:GTHX)

$21.51
+0.45 (+2.14 %)
(As of 10/14/2019 12:43 PM ET)
Today's Range
$20.74
Now: $21.51
$21.82
50-Day Range
$20.99
MA: $32.60
$40.32
52-Week Range
$13.87
Now: $21.51
$48.43
Volume5,414 shs
Average Volume620,284 shs
Market Capitalization$807.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$9.65 per share

Profitability

Net Income$-85,290,000.00

Miscellaneous

Employees84
Market Cap$807.06 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.


G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics Inc (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.09. View G1 Therapeutics' Earnings History.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for G1 Therapeutics.

What price target have analysts set for GTHX?

7 brokers have issued 12-month price objectives for G1 Therapeutics' stock. Their predictions range from $45.00 to $74.00. On average, they anticipate G1 Therapeutics' share price to reach $62.60 in the next twelve months. This suggests a possible upside of 191.0% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.

What is the consensus analysts' recommendation for G1 Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.

What are Wall Street analysts saying about G1 Therapeutics stock?

Here are some recent quotes from research analysts about G1 Therapeutics stock:
  • 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (10/1/2019)
  • 2. HC Wainwright analysts commented, "We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48." (9/11/2019)

Has G1 Therapeutics been receiving favorable news coverage?

News stories about GTHX stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for G1 Therapeutics.

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the folowing people:
  • Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
  • Mr. James Stillman Hanson, Gen. Counsel (Age 47)
  • Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
  • Mr. John Demaree, Chief Commercial Officer (Age 52)
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $21.51.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $807.06 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is http://www.g1therapeutics.com/.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.


MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  422
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel